Ningbo NewBay Medical Technology Co., Ltd. (Headquarters in Ningbo, China, CEO: Zhenhai Shen, NewBay), a subsidiary company of Ningbo Tai Kang Medical Technology Co., Ltd (“Ningbo Tai Kang”), which licensed AskAt Inc.’s EP4 antagonist AAT-007 (generic name: grapiprant) for oncology in China, has filed an IND application with the China Food and Drug Administration.

AskAt Inc. will receive a milestone payment according to the terms of the License Agreement executed between Ningbo Tai Kang and AskAt as a result of achieving this filing.